Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 2:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 130 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Duloxetine Clear all
Completed Phase 3 Interventional

Duloxetine Compared With Placebo in the Prevention of Relapse in Generalized Anxiety Disorder

NCT00122863
View directory record Official record
Conditions
Anxiety Disorders
Interventions
Duloxetine Hydrochloride, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
19
States / cities
Sherman Oaks, California • Fort Myers, Florida • Atlanta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2007 · Synced Sep 3, 2026, 2:35 AM EDT
Completed Phase 2 Interventional Results available

Duloxetine Versus Pregabalin for Alcohol Dependence

NCT00929344
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Pregabalin, Duloxetine, Standardized behavioral therapy, Placebo
Drug · Behavioral
Lead sponsor
The Scripps Research Institute
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Sep 3, 2026, 2:35 AM EDT
Not listed Phase 4 Interventional

Acute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A)

NCT04245436
View directory record Official record
Conditions
Anxiety, Depressive Symptoms
Interventions
Duloxetine, Escitalopram
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
12 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Sep 3, 2026, 2:35 AM EDT
Completed Phase 3 Interventional Results available

A Study in the Treatment of Children and Adolescents With Major Depressive Disorder

NCT00849901
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
duloxetine, Placebo, fluoxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
7 Years to 17 Years
Enrollment
337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
24
States / cities
Costa Mesa, California • Irvine, California • Palo Alto, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2017 · Synced Sep 3, 2026, 2:35 AM EDT
Recruiting Phase 2 Interventional

SPENDD: Quantitative Sensory Testing and Analgesic Response for Painful Peripheral Neuropathy.

NCT06614322
View directory record Official record
Conditions
Painful Peripheral Neuropathy, Diabetic Peripheral Neuropathic Pain (DPN), Chemotherapy Induced Peripheral Neuropathy (CIPN), Idiopathic Peripheral Neuropathy
Interventions
Pregabalin, Duloxetine, Placebo
Drug · Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 80 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Boston, Massachusetts • New York, New York • Rochester, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 3, 2026, 2:35 AM EDT
Not listed Phase 4 Interventional

Cymbalta for Depression as a Complication of Bereavement

NCT00658931
View directory record Official record
Conditions
Depression, Bereavement
Interventions
Drug treatment with Cymbalta
Drug
Lead sponsor
Jefferson Clinic, P.C.
Other
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 11, 2010 · Synced Sep 3, 2026, 2:35 AM EDT
Completed Phase 3 Interventional

To Evaluate the Safety of Duloxetine in Patients With Stress Urinary Incontinence

NCT00190645
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
Duloxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 25, 2007 · Synced Sep 3, 2026, 2:35 AM EDT
Completed Phase 4 Interventional Results available

Does Duloxetine Reduce Sub-Acute Pain After Knee Arthroplasty?

NCT02005601
View directory record Official record
Conditions
Total Knee Arthroplasty
Interventions
Placebo, Duloxetine 60mg
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
25 Years to 75 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2017 · Synced Sep 3, 2026, 2:35 AM EDT
Completed Phase 4 Interventional Results available

Study of Milnacipran in Patients With Inadequate Response to Duloxetine for the Treatment of Fibromyalgia

NCT01077375
View directory record Official record
Conditions
Fibromyalgia
Interventions
Placebo, Milnacipran
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
26
States / cities
Sacramento, California • Cromwell, Connecticut • Danbury, Connecticut + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2012 · Synced Sep 3, 2026, 2:35 AM EDT
Terminated Phase 4 Interventional Results available

Switching to Duloxetine to Ameliorate SSRI-Induced Sexual Dysfunction

NCT00398632
View directory record Official record
Conditions
Depression
Interventions
Duloxetine
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Sep 3, 2026, 2:35 AM EDT
Recruiting Phase 2 Interventional

Efficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough

NCT05110144
View directory record Official record
Conditions
Refractory Chronic Cough
Interventions
Duloxetine 30 MG, Duloxetine 60 MG, Amitriptyline 25 MG, Amitriptyline 50 MG, Placebo 30 MG, Placebo 60 MG
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 3, 2026, 2:35 AM EDT
Completed Phase 3 Interventional Results available

S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy

NCT01598298
View directory record Official record
Conditions
Breast Cancer, Musculoskeletal Complications, Pain
Interventions
duloxetine hydrochloride, placebo
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Up to 120 Years · Female only
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
714
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Jonesboro, Arkansas + 475 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2022 · Synced Sep 3, 2026, 2:35 AM EDT
Not listed Phase 3 Interventional

Open-Label Duloxetine Monotherapy in the Treatment of Posttraumatic Stress Disorder

NCT00583193
View directory record Official record
Conditions
Posttraumatic Stress Disorders
Interventions
Duloxetine hydrochloride
Drug
Lead sponsor
Canive, Jose M., M.D.
Individual
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Dec 30, 2007 · Synced Sep 3, 2026, 2:35 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Urge Incontinence Bladder Overactivity Study

NCT00475696
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Duloxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 20, 2007 · Synced Sep 3, 2026, 2:35 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Cymbalta for Fibromyalgia Pain - Predictive Value of Small Fiber Changed

NCT01619566
View directory record Official record
Conditions
Fibromyalgia
Interventions
Duloxetine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 70 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 8, 2019 · Synced Sep 3, 2026, 2:35 AM EDT
Completed Phase 3 Interventional

Duloxetine Versus Placebo for Fibromyalgia

NCT00489073
View directory record Official record
Conditions
Fibromyalgia
Interventions
duloxetine, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 20, 2007 · Synced Sep 3, 2026, 2:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Behavioral Effects of Drugs: Inpatient (36) (Alcohol, Duloxetine, and Methylphenidate)

NCT03575403
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Alcohol, Placebos, Duloxetine (60 MG), Methylphenidate, Duloxetine (30 MG)
Drug
Lead sponsor
Craig Rush
Other
Eligibility
21 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 3, 2026, 2:35 AM EDT
Completed Phase 2Phase 3 Interventional

Effects of Duloxetine vs. Escitalopram on Heart Rate Variability in Depression

NCT00215228
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
duloxetine vs. escitalopram
Drug
Lead sponsor
Duke University
Other
Eligibility
20 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 20, 2014 · Synced Sep 3, 2026, 2:35 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Double Blind Trial of Duloxetine in Chronic Fatigue Syndrome

NCT00375973
View directory record Official record
Conditions
Fatigue Syndrome, Chronic
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 20, 2015 · Synced Sep 3, 2026, 2:35 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder

NCT00384033
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Desvenlafaxine Succinate Sustained-Release (DVS SR), Placebo, Duloxetine 60 mg/day
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
638 participants
Timeline
2006 – 2007
U.S. locations
22
States / cities
Beverly Hills, California • Burbank, California • Encino, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Sep 3, 2026, 2:35 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

NCT01153009
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Vortioxetine, Duloxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
56
States / cities
Beverly Hills, California • Chino, California • Garden Grove, California + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Sep 3, 2026, 2:35 AM EDT
Completed Phase 2 Interventional

Altering The Transition From Acute to Chronic Pain (ATTAC-Pain)

NCT03315533
View directory record Official record
Conditions
Musculoskeletal Pain
Interventions
Duloxetine 30 milligrams (MG), Duloxetine 60 milligrams (MG), Placebo Oral Tablet
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Sep 3, 2026, 2:35 AM EDT
Completed Phase 3 Interventional

Duloxetine vs Placebo in the Treatment of General Anxiety

NCT00475969
View directory record Official record
Conditions
Anxiety
Interventions
duloxetine, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 20, 2007 · Synced Sep 3, 2026, 2:35 AM EDT
Terminated Phase 2 Interventional Results available

Feasibility Study of Duloxetine in the Treatment of Depression in Patients With Traumatic Brain Injury

NCT01223001
View directory record Official record
Conditions
Traumatic Brain Injury, Depression
Interventions
Duloxetine, Sugar pill
Drug
Lead sponsor
Rehabilitation Hospital of Indiana
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 16, 2014 · Synced Sep 3, 2026, 2:35 AM EDT